Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $7.2 million.

  • Novartis Ag's Shares Outstanding (Diluted Average) rose 2180.58% to $7.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.2 million, marking a year-over-year increase of 2180.58%. This contributed to the annual value of $7.2 million for FY2025, which is 2180.58% up from last year.
  • According to the latest figures from Q4 2025, Novartis Ag's Shares Outstanding (Diluted Average) is $7.2 million, which was up 2180.58% from $5.9 million recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Shares Outstanding (Diluted Average) ranged from a high of $10.6 million in Q4 2021 and a low of $910000.0 during Q1 2021
  • Its 5-year average for Shares Outstanding (Diluted Average) is $3.4 million, with a median of $2.8 million in 2022.
  • As far as peak fluctuations go, Novartis Ag's Shares Outstanding (Diluted Average) soared by 20198.86% in 2021, and later crashed by 7412.98% in 2022.
  • Novartis Ag's Shares Outstanding (Diluted Average) (Quarter) stood at $10.6 million in 2021, then plummeted by 74.13% to $2.8 million in 2022, then soared by 49.09% to $4.1 million in 2023, then soared by 43.17% to $5.9 million in 2024, then increased by 21.81% to $7.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $7.2 million for Q4 2025, versus $5.9 million for Q3 2025 and $3.9 million for Q2 2025.